

AperTO - Archivio Istituzionale Open Access dell'Università di Torino

Association of aplastic anaemia and lymphoma: a report from the severe aplastic anaemia working party of the European Society of Blood and Bone Marrow Transplantation

This is a pre print version of the following article:

Original Citation:

Availability:

This version is available <http://hdl.handle.net/2318/1660559> since 2018-02-23T10:33:50Z

Published version:

DOI:10.1111/bjh.15074

Terms of use:

Open Access

Anyone can freely access the full text of works made available as "Open Access". Works made available under a Creative Commons license can be used according to the terms and conditions of said license. Use of all other works requires consent of the right holder (author or publisher) if not exempted from copyright protection by the applicable law.

(Article begins on next page)

Association of aplastic anaemia and lymphoma: a report from the severe aplastic anaemia working party of the European Society of Blood and Bone Marrow Transplantation

Although anecdotal reports showing the uncommon association of aplastic anaemia (AA) and lymphoma have been published (Dorr *et al*, 1996; Koziner *et al*, 1975; Medinger *et al*, 2012; Suzuki *et al*, 2009; Veidt *et al*, 2005; Yoshioka *et al*, 1999; Zonder *et al*, 2002), data related to its incidence, diagnostic characteristics and centre management strategies are lacking. The Severe Aplastic Anaemia Working Party of the European Society of Blood and Bone Marrow Transplantation (SAAWP-EBMT) aimed to evaluate the diseases characteristics and treating centre attitudes regarding the treatment and outcome of patients suffering from both AA and lymphoma. Between 2013–2015, we collected data of patients with this combination. Congenital bone marrow failures, as well as AA or lymphoma that occurred after haematopoietic stem cell transplantation (HSCT) were excluded.

Eighty-three (28%) of the 294 EBMT centres contacted participated in this study; 13 (16%) centres, from 7 different countries, reported the 26 cases included in the study. AA was diagnosed between 1983–2015; median age at AA diagnosis was 57 (10–78) years, 16 patients (62%) were male, 13 patients had severe AA (SAA) and 6 very severe AA (vSAA). Of the 18 cases investigated for paroxysmal nocturnal haemoglobinuria (PNH) clones by flow cytometry, two had a small clone, without clinical PNH signs or symptoms. Cytogenetics was available in 22/26(85%) cases; only one had an anomaly (trisomy 12). At AA diagnosis, 85% and 86% of patients required red blood cell and platelet transfusions, respectively. Lymphoma was diagnosed between 1958 and 2015, at a median age of 52 years (12–78). Five patients (19%) had Hodgkin lymphoma (HL) for which histopathology was available in 4 cases: 2 lymphocyte predominant type, 1 nodular sclerosis and 1 mixed cellularity. Non-Hodgkin lymphoma (NHL) was reported in 21 (81%) patients: 19 (73%) had a B-cell NHL and two patients an unspecified lymphoma. A subtype of B-cell NHL was reported in 18 cases: 4 diffuse large B-cell, 3 lymphoplasmacytic, 3 follicular, 3 nodal marginal zone, 2 chronic lymphocytic leukaemia, 1 splenic marginal zone, 1 mantle cell and 1 plasma cell neoplasm. The lymphoma was treated in 23 cases (91%).

Lymphoma was detected at three different times with respect to AA (Fig 1): 11 patients presented with lymphoma

before AA, 7 patients were simultaneously diagnosed with AA and lymphoma, and 8 patients presented with lymphoma after AA diagnosis.

Patients presenting AA and lymphoma simultaneously were significantly older compared to the other times of presentation (Table I). HL was mainly observed in patients presenting lymphoma before AA (4 out of 5 HL). Various underlying pathogenic mechanisms may be involved in the different times of presentation. AA occurring after lymphoma and/or its treatment could have a different cause of marrow failure than typical AA. Alkylating agents included in lymphoma therapy, could lead to exhaustion of the stem cell pool, resulting in subsequent marrow failure (Gobbi *et al*, 2009). In line with this hypothesis, we found that more patients with AA occurring after lymphoma failed to respond to standard immunosuppressive therapy (IST) and needed a HSCT (Table I). Likewise, the use of purine nucleoside analogues have significant cytotoxic activity, resulting in prolonged lymphocyte depletion, especially in CD4 T-cells; this immune dysregulation might facilitate autoimmunity. In our series, only one patient was treated with fludarabine before the development of AA. When AA and lymphoma occur concomitantly, AA may emerge as a paraneoplastic autoimmune phenomenon of the lymphoma (Chandor, 1988), although our data could not fully confirm this hypothesis. In 3 of the 7 cases with concomitant presentation, the lymphoma was treated first, aiming to control both diseases; however, after chemotherapy, complete remission of the lymphoma was achieved in 2 of these cases but the AA did not respond and needed subsequently therapy. Furthermore, lymphoma has been reported following administration of anti-thymocyte globulin (ATG) (Calistri *et al*, 2006). In this series, lymphoma was diagnosed in 2 patients within one year after ATG therapy; in both cases, the AA remained active at lymphoma diagnosis (1 partial response, 1 non-responder). In this study, none of the reported lymphomas were Epstein–Barr virus associated. All these pathophysiological hypotheses concerning the association of AA and lymphoma are conceivable, but need to be proven.

In patients where AA appeared first, the standard AA approach for therapy was observed, thus all patients received




Fig 1. Order of lymphoma appearance with regard to aplastic anaemia. AA, aplastic anaemia; HL, Hodgkin lymphoma; NHL, non-Hodgkin lymphoma; SAA, severe aplastic anaemia; vSAA, very severe aplastic anaemia.

ATG. The absence of HSCT as first line treatment is explained by the exclusion criteria of this study. The management of AA was more heterogeneous when both diseases appeared simultaneously or when AA occurred after lymphoma. When presentation was concomitant, although 6 of the 7 patients had SAA or vSAA, only 1 patient received a standard IST including ATG. In 3 cases the lymphoma was treated first, and 2 cases received treatment including other drugs, such as alemtuzumab and steroids, aiming to simultaneously treat both diseases. The centres reported that therapy was oriented to treat the more severe, or symptomatic disease. When AA occurred after the lymphoma, the management approach was also heterogeneous, including one patient who received HSCT as first line therapy.

Patients' outcome analysis showed that 17 (65%) patients were alive at last follow-up. The 9 deaths included 6 due to AA (either from the disease itself or HSCT-related cause), 1 after HSCT to treat the lymphoma; 1 from a second malignancy and 1 due to advanced age. AA-related causes of deaths were significantly more frequent than lymphoma-related deaths ($P < 0.001$).

The presented data do not enable clear recommendations to be made regarding the management of AA when associated with lymphoma. However, centre preferences can be discussed. When AA presents first, it is clear that AA has to be treated according to its severity following the standard of care. The appearance of lymphoma later in the course does not seem to affect the prognosis. The decision to treat AA is more controversial when lymphoma appears before or at the same time as AA. Given that the outcome of AA seems to prevail over that of lymphoma, patients should receive, whenever possible, standard treatment for AA. Given there is a probability of stem cell exhaustion after lymphoma treatment (such cases will never respond to IST), an allogeneic HSCT should be considered and, if indicated, a search of a stem cell donor initiated.

In conclusion, the combination of AA and lymphoma is a rare and heterogeneous event, in which the outcome is mainly affected by the AA rather than the lymphoma. We believe that continuing systematic evaluation of such rare presentations, together with the recent achievement of molecular aspects of both diseases, might contribute to the

Table I. Association of AA and lymphoma. Comparison of disease presentation, treatment and outcome.

| Parameters | Lymphoma before AA | Simultaneous Lymphoma and AA | Lymphoma after AA | <i>P</i> |
|--|--------------------|------------------------------|-------------------|----------|
| <i>N</i> | 11 | 7 | 9 | |
| Males | 7 (64%) | 5 (71%) | 4 (50%) | ns |
| Age at AA, years, (range) | 49 (20–73) | 68 (47–78) | 41 (9–67) | 0.02 |
| Age at lymphoma, years (range) | 46 (12–71) | 68 (47–78) | 47 (14–70) | 0.02 |
| Age at 1st diagnosis, years (range) | 49 (12–73) | 68 (47–78) | 41 (9–67) | 0.01 |
| Median interval 1st–2nd diagnosis, in months | 15 (3–436) | na | 45 (4–135) | |
| AA Severity | | | | |
| vSAA | 3 | 1 | 2 | |
| SAA | 5 | 5 | 3 | ns |
| Non-severe AA | 3 | 1 | 1 | |
| Unknown | 1 | 0 | 2 | |
| Type of lymphoma | | | | |
| B-cell lymphoma | 7 | 6 | 6 | |
| HL | 4 | 1 | 0 | 0.05 |
| Unspecified lymphoma | 0 | 0 | 2 | |
| Treatment | | | | |
| AA Therapy | | | | |
| ATG containing | 4 | 1 | 8 | |
| CSA alone | 5 | 2 | 0 | |
| G-CSF | 1 | 0 | 0 | 0.005 |
| Alemtuzumab | 0 | 1 | 0 | |
| HSCT | 1 | 0 | 0 | |
| No treatment | 0 | 3 | 0 | |
| Response to IST | | | | |
| Complete response | 2 | 1 | 3 | |
| Partial response | 1 | 1 | 3 | |
| No response | 8 | 1 | 2 | |
| Unknown | 0 | 1 | 0 | |
| First line therapy of lymphoma | | | | |
| CHOP-line/HL treatment | 6 | 2 | 3 | |
| Rituximab | 2 | 2 | 3 | |
| Steroid alone | 1 | 1 | 0 | ns |
| Radiotherapy | 1 | 0 | 0 | |
| No treatment | 0 | 2 | 0 | |
| unknown | 1 | 0 | 2 | |
| Lymphoma response after therapy | | | | |
| Complete remission | 6 | 2 | 2 | |
| Partial remission | 1 | 0 | 3 | |
| No response | 2 | 3 | 2 | |
| Unknown | 2 | 0 | 1 | |
| All HSCT | 6 (54%) | 2 (29%) | 3 (31%) | ns |
| Indicated for AA | 6 | 1 | 0 | 0.01 |
| Indicated for lymphoma | 0 | 1 | 3 | |
| Outcome | | | | |
| Alive | 6 (55%) | 5 (71%) | 6 (75%) | |
| Death | 5 (45%) | 2 (29%) | 2 (25%) | |
| Causes of death | | | | |
| AA and/or its treatment | 3 | 2 | 1 | |
| Lymphoma and/or its treatment | 0 | 0 | 1 | |
| Others | 2 | 0 | 0 | |

AA, aplastic anaemia; ATG, anti-thymocyte globulin; CHOP, cytoxan, adriamycin, vincristine and prednisone; CSA, ciclosporin; G-CSF, granulocyte colony-stimulating factor; HL, Hodgkin lymphoma; HSCT, haematopoietic stem cell transplantation; SAA, severe aplastic anaemia; vSAA, very severe aplastic anaemia.

understanding and better management of these patients in the future.

Acknowledgements

We thank all participating centres and data managers for their valuable contribution in this study.

Reporting EBMT centres (Centre Identification code: country, city, investigator/s, number of patients): 202: Switzerland, Basel, Michael Medinger/Jakob Passweg, 4; 205: United Kingdom, London, Edward Kanfer, 1; 207: France, Paris, Regis Peffault de la Tour, 1; 221: Switzerland, Bern, Alicia Rovó, 1; 231: Italy, Torino, 1; 252: France, Creteil, Sebastien Maury, 1; 253: France, Nantes, Patrice Chevallier, 2; 305: Italy, Torino, Paola Quarello, 1; 539: United Kingdom, London, Mickey Koh, 1; 565: Netherlands, Maastricht, Harry Schouten, 1; 590: Germany, Berlin, Wolfgang Blau, 1; 613: Spain, Barcelona, Jose M Ribera, 2; 763: United Kingdom, London, Austin Kulasekararaj/Anita Hill, 9.

Authorship contributions

AR served as the principal investigator for this study; AR; RPdeL; AT; ARis; JP; JM and CD contributed to the study design. AR; AK; MM; PC; JMR; RPdeL; CK; EK; BB; SM; PQ; MBCK; HS; IWB; AT; AH; ARis; JP; JM; PD and CD contributed to the data collection. AR; CK; SI; AT and CD contributed to data and statistical analysis. AR wrote the paper, AK; MM; PC; JMR; RPdeL; CK; SI; EK; BB; SM; PQ; MBCK; HS; IWB; AT; AH; ARis; JP; JM; PD and CD revised and agreed with this manuscript.

Disclosure of conflicts of interest

The authors have no conflicts of interest to disclose.

Alicia Rovó¹

Austin Kulasekararaj²

Michael Medinger³

Patrice Chevallier⁴

Jose M. Ribera⁵

References

- Calistri, E., Tiribelli, M., Battista, M., Michelutti, A., Corbellino, M., Viale, P., Fanin, R. & Damiani, D. (2006) Epstein-Barr virus reactivation in a patient treated with anti-thymocyte globulin for severe aplastic anemia. *American Journal of Hematology*, 81, 355–357.
- Chandor, S.B. (1988) Autoimmune phenomena in lymphoid malignancies. *Clinics in Laboratory Medicine*, 8, 373–384.
- Dorr, V., Doolittle, G. & Woodroof, J. (1996) First report of a B cell lymphoproliferative disorder arising in a patient treated with immune

- suppressants for severe aplastic anemia. *American Journal of Hematology*, 52, 108–113.
- Gobbi, P.G., Valentino, F., Danova, M., Morabito, F., Rovati, B., Mammi, C., Gentile, M., Merli, F., Stelitano, C., Luminari, S., Quintana, G., Iannitto, E., Brugiatielli, M. & Federico, M. (2009) Bone marrow stem cell damage after three different chemotherapy regimens for advanced Hodgkin's lymphoma. *Oncology Reports*, 21, 1029–1035.
- Koziner, B., Ellman, L. & Aisenberg, A.C. (1975) Lymphoma presenting as bone marrow failure. *Cancer*, 35, 1426–1429.
- Medinger, M., Buser, A., Stern, M., Heim, D., Halter, J., Rovó, A., Tzankov, A., Tichelli, A. &

Regis Peffault de Latour⁶

Cora Knol⁷

Simona Iacobelli⁸

Edward Kanfer⁹

Benedetto Bruno¹⁰

Sébastien Maury¹¹

Paola Quarello¹²

Mickey B. C. Koh¹³

Harry Schouten¹⁴

Igor W. Blau¹⁵

André Tichelli³

Anita Hill¹⁶

Antonio Risitano¹⁷

Jakob Passweg³

Judith Marsh²

Peter Dreger¹⁸

Carlo Dufour¹⁹

on behalf of the Severe Aplastic Anaemia Working Party of the EBMT

¹University Hospital of Bern, Bern, Switzerland, ²King's Denmark Hill Campus, London, UK, ³University Hospital of Basel, Basel, Switzerland,

⁴University Medical Centre, Nantes, France, ⁵Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Jose Carreras Research Institute, Badalona, Spain, ⁶Hopital St. Louis, Paris, France, ⁷EBMT Data

Office, Leiden, the Netherlands, ⁸Centro Interdipartimentale di Biostatistica e Bioinformatica, Università Tor Vergata, Rome, Italy, ⁹Imperial

College, London, UK, ¹⁰A.O.U. Città della Salute e della Scienza, Torino, Italy, ¹¹Hôpital Henri Mondor, Creteil, France, ¹²Ospedale Infantile Regina Margherita, Torino, Italy, ¹³St. George's Hospital, London,

UK, ¹⁴University Medical Centre, Maastricht, the Netherlands, ¹⁵Charité - Campus Virchow Klinikum, Berlin, Germany, ¹⁶Leeds Teaching Hospitals, Leeds, UK, ¹⁷University of Napoli, Napoli, Italy,

¹⁸University of Heidelberg, Heidelberg, Germany and ¹⁹G. Gaslini Children's Hospital, Genova, Italy.

E-mail: alicia.rovo@insel.ch

Keywords: aplastic anaemia, lymphoma, lymphoid neoplasms, haematopoietic stem cell transplantation

Passweg, J. (2012) Aplastic anemia in association with a lymphoproliferative neoplasm: coincidence or causality? *Leukemia Research*, 36, 250–251.

Suzuki, Y., Niitsu, N., Hayama, M., Katayama, T., Ishii, R., Osaka, M., Miyazaki, K., Danbara, M., Horie, R., Yoshida, T., Nakamura, N. & Higashihara, M. (2009) Lymphoproliferative disorders after immunosuppressive therapy for aplastic anemia: a case report and literature review. *Acta Haematologica*, 121, 21–26.

Veidt, R.G., Ansari-Lari, A. & Brodsky, R.A. (2005) Severe aplastic anemia associated with paroxysmal nocturnal hemoglobinuria and

lymphoplasmacytic lymphoma. *Leukaemia & Lymphoma*, 46, 1243–1246.

Yoshioka, Y., Kawamata, N., Sato, E., Isobe, Y. & Oshimi, K. (1999) Primary splenic lymphoma

with hypoplastic bone marrow. *Rinsho Ketsueki*, 40, 124–128.

Zonder, J.A., Keating, M. & Schiffer, C.A. (2002) Chronic lymphocytic leukemia presenting in

association with aplastic anemia. *American Journal of Hematology*, 71, 323–327.